MyBiotics Pharma

Clinically Effective Microbiome and Probiotic Products

Health Tech & Life Sciences
Active
Series A Rehovot Founded 2014
Total raised
$11.3M
Last: Undisclosed 2021-02
Stage
Series A
Founded
2014
Headcount
13
HQ
Rehovot
Sector
Health Tech & Life Sciences

About

MyBiotics Pharma is a microbiome company focused on bettering peoples lives and health by greatly improving on existing probiotic solutions. MyBiotics has developed a novel technological platform for the development of microbiome-related drugs and supplements. The companys platform uses innovative formulation, delivery, and culturing methods designed to provide better viability and resistance, and potentially improved colonization and clinical results. Based on this proprietary innovation, MyBiotics has developed three main technologies: MyCrobe, SuperDonor, and Super Donor Select, which are all supported by MyLiveIn, a computational and AI technology platform. After targeting specific medical indications, MyBiotics has now reached the clinical stage with three products. Based on the companys SuperDonor technology, its MBX-SD-201 and MBX-SD-202 products offer safe and reproducible microbiome restoration and may become an alternative for complete microbiome recovery and design using fecal microbiota transplantation. MyBiotics has initiated significant collaborations and development agreements with a variety of pharmaceutical companies and clinical partners in the areas of C. diff, oncology, dermatology, and womens health.

Funding history · 4 rounds · $11.3M total

2021-02
Undisclosed Undisclosed
2018-08
Series A $8.0M
2016-03
Seed $650K
2015-05
Seed $320K

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug DeliveryDrugs Discovery & DevelopmentBiomaterials & Tissue Engineering
Technologies
BiologicalsMicroorganisms
Target customers
Healthcare & Life SciencesHealthcarePatientsLife SciencesPharmaceuticalsConsumersRecreational & LifestyleFitness & Sports
Business model
B2BB2C

Highlights

1 PatentsVerified

Tags

bacteriasupplementsgastroenterologydrug-deliveryoncologycancermicrobiomepharmaceuticalspharma-companiescosmeticsdermatologynutritionartificial-intelligencelife-sciencestherapeuticsskin-carepatientswomen-healthwellnessdrug-developmentconsumerspersonalizationbiotechnologybioconvergence